Indian Market News

Generic user silhouette icon 5paisa Capital Ltd
  • 11th Mar 2025
  • 3 min read

Indian equities are poised for a rebound in 2025, as growth is projected to recover and valuations reach their most attractive levels since the COVID-19 pandemic, according to a research report by Morgan Stanley. The brokerage anticipates India's

Generic user silhouette icon 5paisa Capital Ltd
  • 11th Mar 2025
  • 3 min read

At the upcoming first board meeting under the leadership of newly appointed Chairperson Tuhin Kanta Pandey, the Securities and Exchange Board of India (SEBI) is set to deliberate on several key regulatory proposals. The agenda includes introducing UP

Generic user silhouette icon 5paisa Capital Ltd
  • 11th Mar 2025
  • 3 min read

Shares of private lender IndusInd Bank Ltd. plummeted by 20% during the market's opening session on March 11, following the revelation of discrepancies in its derivatives portfolio. As of 9:50 AM, IndusInd Bank share price was trading at ₹720.35

Generic user silhouette icon 5paisa Capital Ltd
  • 10th Mar 2025
  • 3 min read

Markets regulator SEBI has implemented a more stringent regulatory framework for SME IPOs, introducing a profitability requirement and capping the Offer-for-Sale (OFS) component at 20%. These reforms aim to facilitate SMEs with a solid track recor

Generic user silhouette icon 5paisa Capital Ltd
  • 10th Mar 2025
  • 3 min read

Indian stock markets have staged a significant recovery in recent trading sessions, demonstrating resilience despite weak global sentiment amid intensifying trade tensions and signs of economic slowdown in the U.S. The domestic equity markets are att

Generic user silhouette icon 5paisa Capital Ltd
  • 10th Mar 2025
  • 4 min read

The Indian stock market broke its three-week losing streak, posting a strong rebound fueled by positive global and domestic developments, particularly surrounding US tariff-related updates. This renewed optimism among investors on Dalal Street. In

Generic user silhouette icon 5paisa Capital Ltd
  • 10th Mar 2025
  • 2 min read

At the Moneycontrol Global Wealth Summit, a panel of leading money managers emphasized the importance of caution when investing in the broader market, noting that valuations may not have fully stabilized. Prashant Jain, a seasoned investor and fou

Generic user silhouette icon 5paisa Capital Ltd
  • 10th Mar 2025
  • 2 min read

The finalization of the share purchase agreement for IDBI Bank's privatization is expected in March, according to a CNBC-TV18 report on March 10. Government’s Privatization Strategy Government officials stated that the Centre aims to complete

Generic user silhouette icon 5paisa Capital Ltd
  • 10th Mar 2025
  • 3 min read

India is working to expedite a crucial bilateral trade agreement with the United States. Amid increasing concerns over the broad tariffs imposed by US President Donald Trump, recent reports indicate that officials from both nations are eager to final

Generic user silhouette icon 5paisa Capital Ltd
  • 10th Mar 2025
  • 3 min read

The Reserve Bank of India (RBI) is likely to persist in its efforts to support the rupee, despite speculation that Governor Sanjay Malhotra might adopt a different stance, according to a report by Mint. A senior government official informed Mint t

Generic user silhouette icon 5paisa Capital Ltd
  • 10th Mar 2025
  • 2 min read

After a five-month decline, the Indian stock market has lost its long-held valuation advantage over the U.S. For the first time since 2009, the BSE Sensex is trading at a lower price-to-earnings (P/E) ratio than the Dow Jones Industrial Average, as p

Generic user silhouette icon 5paisa Capital Ltd
  • 10th Mar 2025
  • 2 min read

Sun Pharmaceutical Industries share, India's largest drug maker by revenue, has announced its decision to acquire Nasdaq-listed Checkpoint Therapeutics in a $355 million deal. The acquisition, confirmed on March 10, 2025, will help Sun Pharma enhance

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form